A randomized, open-label study of prophylactic administration of PEGASYS [peginterferon alfa-2a] plus ribavirin [COPEGUS; Roche] after liver transplantation on hepatitis C recurrence in patients with hepatitis C.

Trial Profile

A randomized, open-label study of prophylactic administration of PEGASYS [peginterferon alfa-2a] plus ribavirin [COPEGUS; Roche] after liver transplantation on hepatitis C recurrence in patients with hepatitis C.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2010

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PHOENIX
  • Most Recent Events

    • 30 Oct 2009 Results presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 02 Dec 2008 Status changed from active, no longer recruiting to completed.
    • 19 Mar 2008 The expected completion date for this trial is now 1 Oct 2008, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top